Myocardial regeneration can be induced with the implantation of a variety of myogenic and angiogenic cell types. More than 150 patients have been treated with cellular cardiomyoplasty worldwide, 18 patients have been treated by our group. Cellular cardiomyoplasty seems to reduce the size and fibrosis of infarct scars, limit postischemic remodelling, and restore regional myocardial contractility. Techniques for skeletal myoblasts culture and ex vivo expansion using autologous patient serum (obtained from plasmapheresis) have been developed by our group. In this article we propose (1) a total autologous cell culture technique and procedures for cell delivery and (2) a clinical trial with appropriate endpoints structured to determine the efficacy of cellular cardiomyoplasty. 
Moreover denervated skeletal myoblasts could progressively become atrophic.
Bone Marrow Cells
There are four cell lineages that can be isolated from bone marrow: hematopoietic stem cells, mesenchymal stem cells [12] , multipotent adult progenitor cells [13, 14] , and progenitor endothelial cells [15] . The mesenchymal stem cells (called also bone marrow stromal cells) are capable of giving rise to multiple cell lines.
The main problem remaining with bone marrow cells is that they may differentiate into fibroblasts after implantation in a fibrotic scar, with the risk of becoming a "scar within a scar." Thus the importance of the implantation microenvironment. The apparent transdifferentiation of stem cells may be due to mere cell fusion with parenchymal cells, endowing the stem cell with specialized function [16] .
Experimentally bone marrow stromal cells can be induced to differentiate in vitro into myocytes before transplant using a coculture system with cardiomyocytes [17, 18] or by including 5-azacytidine in the cultures [19] . This approach can be compromised for clinical trials in terms of potential cell mutations by 5-azacytidine. In vitro electrostimulation of cell cultures is experimentally used by our group for predifferenciation of stem cells in a myogenic lineage [20] .
Peripheral blood stem cells are similar to those obtained from bone marrow aspiration. These cells can be previously mobilized from bone marrow by administration of cytokines in the form of stimulating growth factors, for example granulocyte-colony stimulating factor. Statins can also be used for cell mobilization [21] . The maximum mobilization effect occurs on the fifth day of administration, afterwards a mononuclear cell-rich fraction is isolated. Side effects during cell mobilization should be carefully evaluated, for example leucocytosis and increase of platelet number (responsible of coagulation abnormalities), splenomegaly.
Smooth Muscle Cells
Smooth muscle cells can be obtained from a segment of artery, the vermiform appendix or the uterus during laparoscopy. Experimental studies have demonstrated successful in vitro cell expansion. After implantation in pathologic myocardium, smooth muscle cells proliferate and hypertrophy in response to the stress of cardiac contractions. Cell engraftment has been demonstrated to be related to the recovery of myocardial elasticity and reduction of fibrotic tissue, improved determinants of diastolic function have been observed [22] . These cells do not contract spontaneously after myocardial implantation.
Cardiomyocytes
Fetal and neonatal cardiomyocytes have been successfully grafted into the myocardium after in vitro expansion. The presence of intercalated disks and connexin 43, a marker of gap junctions required for cell to cell electrical coupling, has been experimentally demonstrated within grafted cardiomyocytes and between grafted cells and host myocytes resulting in improved systolic and diastolic ventricular function. In addition to availability, the clinical application of fetal and neonatal cells raises immunologic and ethical questions [23] .
Adult cardiomyocytes present several drawbacks for use in myocardial regeneration owing to the difficulty to expand in the culture medium. In fact adult cardiomyocytes do not divide as they are terminally differentiated cells [24] . Furthermore cardiac cells require adequate vascular supply to survive in infarcted areas, in contrast to skeletal myoblasts which can tolerate an ischemic environment.
Endothelial Cells
Vascular endothelial cells can be harvested from the intima of autologous arteries or veins and be used to induce angiogenesis and neovascularization [25] . Ex-vivo expanded mature endothelial cells had been experimentally transplanted in ischemic myocardium and limbs, this approach presents the advantage of initiate and promote angiogenesis without the limitations of the release of a single protein (vascular endothelial growth factor, basic fibroblast growth factor). Endothelial cells induce an extensive capillary network, but they might not induce the formation of sufficient conduit vessels to regenerate postinfarction myocardial scars. The succesive association of angiogenic and myogenic cell therapy should be beneficial, since prevascularization of myocardial scars may improve local conditions for myogenic cell survival (preconditioning).
Embryonic Cells
Embryonic stem cells can be isolated only from the inner cell mass of blastocysts (on day 6 of development), as the external cell mass of blastocyst will become the placenta. These cells are characterized by their capacity to proliferate in an undifferentiated state for a prolonged period in culture. Afterward they can differentiate into every tissue type in the body, forming derivatives of all three germ layers: ecto, meso, and endoderm. Unfortunately their clinical application raises immunologic barriers and bioethical dilemmas [26] and risks of teratoma formation 
Cell Lines
Cell lines derived from different cell types (stem cells, endothelial cells, and so forth) are commercially produced by cellular biology laboratories. The main drawback of immortalized cultured myogenic or angiogenic cell lines is the potential for tumorogenesis. Unless resolved this will limit the clinical application of this approach. 
Atrial Cardiomyocytes as Cardiac Pacemaker

Mechanisms of Beneficial Effects
The main mechanisms involved determining the beneficial effects of cellular cardiomyoplasty appear to be: reduction of size and fibrosis of infarct scars, limitation of postischemic ventricular remodeling, improvement of left ventricular wall thickening and compliance (diastolic pressure-strain relationship), and increase in regional myocardial contractility (Table 2) [23] , in a canine model of idiopathic dilated cardiomyopathy [15] , and in doxorubicin-induced heart failure [33] . On the basis of these experimental results cellular CMP may improve heart function in patients with nonischemic cardiomyopathy. The grafted cells appear to better survive in the host myocardium because myocardial irrigation in this pathology is not significantly impaired. 
virus (HIV), antihepatitis B-C virus (HBV, HCV), immunoglobulin (Ig) M anticytomegalovirus (CMV), HbsAG, and human T-cell leukemievirus.
The following is a description of the technique used by our group to perform myogenic cellular CMP (Table 3) .
Skeletal Muscle Biopsy
Three weeks before cellular CMP, a biopsy sample of the thigh vastus lateralis is taken through a 5-cm incision under local anesthesia. Local anesthetic agents appears to stimulate dormant myogenic cells. A 2-to 3-cm 3 skeletal muscle sample (12 to 18 g) is explanted under sterile conditions (Fig 1) . Immediate fragmentation of the muscle with scissors is performed and then immerged in complete culture medium or in PBS (phosphate buffer solution, GIBCO, Rockville, MD) and kept at 4°C. The procedure for cell isolation and culture should start as soon as possible so as to guarantee maximun cell survival. However samples can be stored in an appropriate container at low temperature and secondarily transported to the laboratory. Fig 2) . The cell number can be scaled up by repeated passaging in a multiple-tray cell factory or using rotary cell culture systems (Synthecon, Houston, TX). Bacterial (aerobic and anaerobic tests), viral, and fungal controls should be performed at each step of the cell culture procedure.
Cell Isolation and In Vitro Expansion
Fibroblast Removal From Myoblast Culture
In order to reduce the number of fibroblasts and achieve a pure myoblast culture, a preplating step is applied on the first passage. Preplating technique is based on the quicker attachment of fibroblasts compared with satellite cells. Samples in which myoblast purity is below 30% are 
Catheter-Based Cell Implantation
INTRACORONARY. The intravascular delivery is based on the potential migratory properties of some cells which retain their ability to cross the basal lamina (Table 4) . This approach could be reserved for nonischemic cardiomyopathies, since intracoronary cell delivery constitutes microemboli that could potentially decrease blood supply in ischemic patients [33] [34] [35] [36] . 
Clinical Studies
Three clinical trials on cellular CMP have been initiated by our group. 
Myoblast Trial
Cells CD133ϩ
Mobilized mononuclear bone marrow cells have been implanted into postinfarction myocardial scars during CABG. This protocol is based in the utilization of a subpopulation of bone marrow cells, the CD133ϩ progenitors, which have a tendency to differentiate in true angioblasts and muscle cells. Cells are obtained from peripheral blood after mobilization with granulocytecolony stimulating factor. Cell selection is performed using a isolation kit including a magnetic separation column (CliniMACS, Miltenyi Biotec). This approach avoids cell culture procedures [15] . 
Cells for Ischemic Mitral Valve Regurgitation
International Clinical Trials
Comment
Cell transplantation is being recognized as a viable strategy to improve myocardial viability and limit infarct growth. Encouraging experimental results have permitted the clinical application of cellular CMP. In our approach a total autologous myoblast culture procedure was used. The main benefits of human-autologousserum cell expansion is that it can be performed without risk of prion, viral, or zoonoses contamination. Traditional cell cultures techniques involve the use of fetal bovine serum (FBS) for cell growth. Contact of human cells with fetal bovine serum results after 3-week in fixation of animal proteins on the cell surface, representing an antigenic substrate for immunologic adverse events. After cell implantation an inflamatory reaction occurs with subsequent fibrosis. Clinical-pathologic studies performed after cellular CMP showed the transplanted cells were embedded within fibrosis and without neovascularization [51, 59] . This histologic configuration represents a risk for micro-reentry circuits that can in-duce ectopic generation of severe ventricular arrhythmias. When in vitro myoblasts culture is produced using autologous blood serum the risk of arrhythmia is reduced [60] . This obviate the need for the implantation of defibrillators [8, 43, 46, 53] .
The technical approach used to implant the cells could influence the efficacy of cellular CMP. In fact cell mortality after transplantation appears to be more important when grafted in the center of high-fibrotic ischemic scars (decreased oxygen and nutrients supply to the chronic ischemic myocardium) [32] . Implanting the cells mainly in peri-infarct areas and the association with therapeutic angiogenesis may improve cell survival and the results of cellular CMP [2, 61] . The best functional results seems to be obtained in patients presenting a heterogeneous infarct area (patchy appearance), namely a mixture of viable myocardial tissue and multiple small scars. Therefore a "vascularized fibrosis" seems to be a better indication for cellular CMP than a "nonvascularized" postinfarct scar [43] . It is possible that periodically repeated cell injections should be necessary to progressively reduce the size of infarct scars in ischemic cardiomyopathies or to gradually improve diseased myocardium in nonischemic cardiomyopathies. This approach should be simplified by the development of percutaneous catheter-based cell implantation procedures.
Combined cellular transplantation with multisite cardiac pacing is actually under investigation in our department. After skeletal myoblast implantation in a experimental myocardial infarction model, atrial synchronized biventricular pacing was performed using epicardial electrodes. These studies showed improved cell distribution, development of myotubes and increased expression of slow myosin heavy chain isoforms (better adapted at performing cardiac work). In addition, this combined approach should be promoted in patients with indication of atrio-biventricular resynchronisation [8, 62] .
Perspectives
Cell implantation to treat patients with ischemic or dilated cardiomyopathy is a new concept. Data from well-designed clinical studies are needed to confirm the beneficial effects observed in feasibility studies. Directly injecting skeletal myoblasts-derived cells into ischemic myocardium seems to provide the substrate for electrical instability leading to malignant arrhythmia. A number of clinical difficulties remain to be solved, for example concerning the choice of the best cell type and the best cell dose for each cell type. Also the most optimal method to improve cell engraftment after implantation remains to be be identified. Future randomized studies should provide convincing evidence that cellular cardiomyoplasty itself has any beneficial effects as most of the studies have been performed while associating surgical or percutaneous coronary artery revascularization procedures.
The major challenges for future research programs are the preconditioning for predifferentiation of stem cells before transplantation [63, 64] , the improvement of hostcell interactions (mechanical and electrical coupling), and the optimization of the rate of surviving cells after myocardial implantation [65, 66] . The association of cellbased therapeutic angiogenesis before cellular myogenesis seems to be justified in order to induce prevascularization of postinfarct scars. Electrostimulated cellular CMP should play an important role in transforming a passive cell-based procedure to a dynamic cellular support.
